-
公开(公告)号：US20250066318A1
公开(公告)日：2025-02-27
申请号：US18717613
申请日：2022-12-09
Applicant: Prothena Biosciences Limited
Inventor： Stéphane DE LOMBAERT
IPC: C07D401/04 , A61K31/415 , A61K31/4155 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/5415 , C07D231/40 , C07D277/46 , C07D401/12 , C07D403/12 , C07D405/14 , C07D413/04 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/08 , C07D493/04 , C07D493/08 , C07D519/00
Abstract: This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.
-
公开(公告)号：US20250059157A1
公开(公告)日：2025-02-20
申请号：US18923917
申请日：2024-10-23
Applicant: Merck Patent GmbH
Inventor： Brian A. Sherer , Nadia Brugger
IPC: C07D401/04 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , C07D241/42 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
-
公开(公告)号：US20250057817A1
公开(公告)日：2025-02-20
申请号：US18443925
申请日：2024-02-16
Applicant: AMGEN INC.
Inventor： Brian Alan LANMAN , Victor J. CEE , Alexander J. PICKRELL , Anthony B. REED , Kevin C. YANG , David John KOPECKY , Hui-Ling WANG , Patricia LOPEZ , Kate ASHTON , Shon BOOKER , Christopher M. TEGLEY
IPC: A61K31/428 , A61K31/496 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61P35/00 , C07D239/80 , C07D275/04 , C07D401/04 , C07D403/04 , C07D417/04 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/10 , C07D513/04
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US12227484B2
公开(公告)日：2025-02-18
申请号：US18168322
申请日：2023-02-13
Applicant: ARase Therapeutics Inc.
Inventor： Paul Chang , Katherine Widdowson , Lisa J. Ames
IPC: C07D239/80 , C07D405/12 , C07D405/14 , C07D409/12 , C07D417/04 , C07D417/14 , C07D487/12
Abstract: The present invention relates to sulfonamides and related compounds which are inhibitors of PARG and are useful in the treatment of cancer.
-
公开(公告)号：US20250042901A1
公开(公告)日：2025-02-06
申请号：US18903058
申请日：2024-10-01
Applicant: Boehringer Ingelheim International GmbH
Inventor： Pingrong LIU , Craig Andrew MILLER , Maolin YU , Zhonghua ZHANG , Sabine RUPPEL , Anil K. PADYANA
IPC: C07D471/04 , C07D231/12 , C07D401/04 , C07D403/04 , C07D417/04 , C07D417/14 , C07D487/04
Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
-
公开(公告)号：US20250019374A1
公开(公告)日：2025-01-16
申请号：US18709214
申请日：2022-11-10
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Andrew Bogdan , Elliot P. Farney , Jennifer M. Frost , Philip R. Kym , Zhaoming Xiong , Naomi Anne Barton , Claire Anne Marie Cariou-Mumford , Christopher Patrick McMahon , Giuseppe Nano
IPC: C07D417/04 , A61K31/433 , A61K31/454 , C07D417/14
Abstract: The present invention provides for compounds of Formula (I) (I); wherein R2, X, and Z have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.
-
公开(公告)号：US20250011315A1
公开(公告)日：2025-01-09
申请号：US18673598
申请日：2024-05-24
Applicant: Ikena Oncology, Inc.
Inventor： Alfredo C. Castro , Karen J. McGovern , Michael Burke
IPC: C07D417/04 , A61K31/426 , A61P1/00 , A61P29/00 , C07D235/00 , C07D249/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/42 , C07D277/48 , C07D285/135 , C07D333/36 , C07D417/12
Abstract: The present invention provides AHR agonists, compositions thereof, and methods of using the same.
-
公开(公告)号：US12187720B2
公开(公告)日：2025-01-07
申请号：US17370201
申请日：2021-07-08
Inventor： Wei Li , Duane D Miller , Kinsie E. Arnst , Dong-Jin Hwang
IPC: C07D417/14 , A61P35/00 , C07C49/786 , C07D211/14 , C07D213/76 , C07D217/04 , C07D233/64 , C07D277/24 , C07D405/06 , C07D417/04 , C07D417/12
Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
-
公开(公告)号：US20250002994A1
公开(公告)日：2025-01-02
申请号：US18882446
申请日：2024-09-11
Applicant: Illumina Cambridge Limited
Inventor： Nikolai Nikolaevich Romanov , Patrick McCauley , Niall Hynes
IPC: C12Q1/6869 , C07D405/04 , C07D413/04 , C07D417/04 , C07H19/06 , C07H19/16
Abstract: The present application relates to tertiary amine substituted coumarin derivatives and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
-
公开(公告)号：US20240417397A1
公开(公告)日：2024-12-19
申请号：US18701865
申请日：2022-10-14
Applicant: UNIMATEC CO., LTD.
Inventor： Junya SEINO , Rie AOTSU , Keisuke KOKIN
IPC: C07D417/04 , C07D231/20 , C07D231/52 , C07D401/04 , C07D403/04 , C07D405/12 , C07D413/04 , C07D417/12
Abstract: A fluorine-containing pyrazole compound represented by general formula (1), wherein R represents a hydrocarbon group having 1 to 12 carbon atoms; X represents a heterocyclic group containing at least one heteroatom selected from the group consisting of a halogen atom, nitrogen and oxygen as a ring atom, —OA1, and —NA1A2; and A1 and A2 each independently represents a hydrogen atom or an organic group having 1 to 10 carbon atoms.
